We have four Technology and Knowledge Transfer teams: Life Sciences, Physical Sciences, Ceres Agri-Tech, and Arts, Humanities and Social Sciences. Our door is always open for an exploratory chat about how you might develop your ideas commercially.
In the interests of reducing spam, we have removed individual email addresses, but you are welcome to contact one of us directly by using firstname.lastname@enterprise.cam.ac.uk.
Our Technology and Knowledge Transfer teams can help you develop your idea into a commercial opportunity.
Iain is Head of Life Sciences at Cambridge Enterprise, responsible for a team that is working across the life sciences sector from human health therapeutics to agritech and research tools. Iain has a PhD in Organic Chemistry (Sydney) and MBA (Cambridge).
The team has spun-out companies including X01 Therapeutics, Apcintex (now a Centessa company), DIOSynVax, NoBACZ Healthcare, Predictimmune Limited, PhoreMost, Z-factor and Cambridge Epigenetix. Iain, with colleagues from partner universities founded Apollo Therapeutics, a £40 million fund in early stage drug development and launched the Ceres Agritech Knowledge Exchange Partnership. Iain also led discussions with GSK in respect of the University of Cambridge-GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst.
Iain joined Cambridge Enterprise in November 2003.
Phil is Commercialisation Director in the Technology Transfer Team where he works to commercialise technologies from across the life sciences, with a particular interest in new medicines.
University of Cambridge spin out company PolyProx Therapeutics was established in 2019 with Phil’s support, raising £3.4m seed financing.
Prior to joining Cambridge Enterprise, Phil spent 17 years at Cancer Research Technology (CRT), the commercialisation arm of the charity Cancer Research UK, ultimately as Head of Commercial Portfolio. During his time at CRT, Phil established a strategic partnership with Newcastle University, and worked part-time across both organisations in a technology transfer role. Notably he led the formation of Newcastle University’s five-year cancer drug discovery alliance with Astex Pharmaceuticals, initiated Newcastle’s $31m part-monetization of its royalty interest in cancer drug Rubraca, and was CEO of Demuris Limited, a University spin-out company focussed on antibiotic drug discovery.
Phil has a PhD in developmental biology from the MRC’s National Institute for Medical Research (now the Francis Crick Institute).
With an interest in training and coaching, Phil has been a member of PraxisAuril’s Professional Development Committee since May 2013 and helps to design and deliver courses on technology transfer and strategic partnerships.
Phil joined the Cambridge Enterprise team in March 2018.
Terry is responsible for the commercialisation and diffusion of Life Science and health-related technologies and research arising from the University of Cambridge through the creation of new companies, licensing relationships and partnerships.
In the past year, Terry has been responsible for the commercialisation of several Cambridge technologies, including the licensing of stem cell products and cancer risk prediction tools and the development of investment opportunities in the fields of Flu and Ebola vaccines and a number of opportunities related to cell therapy.
Terry was previously the Head of Intellectual Property and Commercial Research at Guy’s and St Thomas’ Hospital for over 10 years, having founded and grown a technology transfer department that commercialised NHS inventions from ‘bedside to business’. There he commercialised a variety of technologies including medical devices, software, imaging technologies, laboratory products, novel formulations, in vitro diagnostics and service based IP. He has also been involved in the creation of novel partnerships for the National Health Service such as Viapath (a £500m pathology joint venture with Serco) and Essentia Trading Ltd (a facilities spin-out company). In addition, Terry supported the formation of technology-based spin-out companies including Cydar and SpOtOn Clinical Diagnostics amongst others and has served as a Director for several spin-out companies. Terry was also responsible for founding a Proof of Concept investment fund and setting up a commercial research and consultancy service within the NHS to interface with industry. Prior to this, Terry was Acting Director of MediChIP, the NHS Innovation Hub for SE/SW London. He then became part of the change management team responsible for the merger of the London NHS Innovation hubs to form a single tech-transfer unit (NHS Innovations London).
Terry has a PhD in immunology and gene silencing and held a postdoctoral research position within the UK’s first stem cell spin-out company, Cerestem Ltd.
Terry joined Cambridge in February 2018.
Rachel is responsible for developing and commercialising new opportunities for all Life Sciences technologies with a focus on therapeutics and diagnostics technologies, medical devices and software, and medical apps.
Rachel’s role includes evaluating new inventions, managing IP protection and helping academics raise translational funding. She also builds teams of experts to develop new opportunities and determines the appropriate route for commercialisation, including licensing and company formation.
Rachel has completed a variety of deals, including a licence with a large US medical company for a technology to revolutionise diabetes treatment. She has particular experience of working in the field of psychiatry and cognition where she has negotiated licences with multiple partners including a US-based molecular diagnostics company. Rachel has helped many academic teams raise translational funding to develop projects at the University.
Before joining Cambridge Enterprise, Rachel worked as a Patent Analyst at Thomson Scientific, specialising in patent searching and patent-based intelligence for the biotech and pharmaceutical industries. Rachel has a BSc in Biology from Imperial College London and a PhD in Virology from the University of Cambridge.
Rachel joined Cambridge Enterprise in November 2006 as a Commercialisation Associate and became Commercialisation Manager in February 2011.
Laura is a Commercialisation Manager in the Technology Transfer Team where she works to commercialise technologies from across the life sciences.
She has experience in identifying, managing, developing and commercialising a range of life sciences IP. She has particular experience of working in the fields of stem cell research, medical devices and drug discovery and has worked on a variety of deals including a licence with a large US medical company for a technology to revolutionise diabetes treatment. Laura has also supported multiple projects under development with Apollo Therapeutics and helped manage the University of Cambridge – GSK Open Innovation Drug Discovery Initiative at the Stevenage Bioscience Catalyst. As part of her role at Cambridge Enterprise, Laura spent five months on secondment as a Business Development Manager at one of Cambridge Enterprise’s spin-out companies, Cambridge Epigenetix.
Before joining Cambridge Enterprise, Laura worked as a postdoctoral researcher at the University of Manchester, studying the regulation of cardiac function and disease by cell signalling pathways. Laura obtained a PhD in Biochemistry from the University of Manchester and a BSc in Biochemistry from the University of York.
Laura joined Cambridge Enterprise in 2011.
Anna Davies is Outreach Manager for Life Sciences. She is focused on growing relationships with researchers working in the life sciences and developing impact through commercialisation.
Before joining Cambridge Enterprise, Anna worked at the University of Cambridge in a variety of roles, co-ordinating a cross-University interdisciplinary network of infectious disease researchers, facilitating research strategy and impact at the Department of Veterinary Medicine. Through a secondment, she also worked closely with academics from across the life sciences to deliver impact case studies for the 2021 Research Excellence Framework (REF) exercise. She joined Cambridge after several years working at the public health laboratories in Porton Down, where she undertook research on aerosol disease transmission and biosafety.
Anna has a degree in Microbiology from the University of Warwick.
Anna joined Cambridge Enterprise in February 2023.
Emma is a Senior Commercialisation Associate in Life Sciences at Cambridge Enterprise responsible for identifying, managing, developing and commercialising a variety of life science IP.
Emma works with academics to secure translational funding and supports further development of IP and licensing – this has led to various multi-£m awards including several from Apollo Therapeutics, the BBSRC Super Follow-on-Fund, The LifeArc Centre for Therapeutics Discovery Programme, and several Seeding Drug Discovery Awards from the Wellcome Trust one of which has subsequently led to a collaboration and licence deal with MSD . She also supports projects as part of the University of Cambridge–GSK Open Innovation Drug Discovery Initiative at the Stevenage BioCatalyst.
Emma led the licence discussions with GSK for the GSK Drug Discovery Partnership with Academia projects at Cambridge, one of which has subsequently led to a licence deal with a US Biotech. She has also supported the licensing of university IP, including to Cambridge spin-outs Cambridge Epigenetix, Morphogen-IX and PolyProx Therapeutics.
Prior to joining Cambridge Enterprise, Emma spent 10 years in the pharma/biotech sector, initially with Oxford Diversity, then BioFocus, involving management of GPCR small molecule drug discovery and optimisation programmes to deliver data packages for subsequent partnering.
Emma has a PhD in Organic Chemistry, 11 academic publications and 4 patent families.
Emma joined Cambridge Enterprise in June 2005.
Helen works across the Life Sciences Team, providing support for the evaluation, IP protection and licensing of technologies arising from the Schools of Biological Sciences and Clinical Medicine.
Recent support has been for the licensing of technologies to Phoremost, Storm Therapeutics and PredictImmune.
Prior to joining Cambridge Enterprise, Helen spent 15 years working for various SME’s in the biotech sector within the Cambridge region, where she held positions in process development and formulation for vaccines and biotherapeutics.
Helen has a PhD in Mucosal Glycobiology from the University of Manchester.
Helen joined Cambridge Enterprise in October 2013.
Ione is a Senior Commercialisation Associate in the Life Sciences team providing support for the evaluation of new inventions, protection of IP, developing commercial opportunities and licensing technologies arising from the University.
Prior to joining Cambridge Enterprise, Ione worked as a Grant Scheme Manager at the Royal Society where she managed a portfolio of international grants. She has a PhD from the UCL Institute of Neurology, which has given her experience of working on translational research. She also has a BSc in Biomedical Sciences from the University of Warwick, and an MSc in Neuroscience from UCL.
Ione joined Cambridge Enterprise in July 2019.
Ione is currently on maternity leave.
Dafne works with Cambridge University Hospitals (CUH) Department of Research and Development and Cambridge Enterprise to identify and commercialise intellectual property originating from research carried out within the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.
She works closely with academics and clinicians to build business opportunities, paving the route to market and securing translational grant funding. She led commercial deals in the domain of stem cells technologies and cancer diagnostics.
She has held senior positions in the area of Market Intelligence and Business Strategy, and worked as an external consultant for several companies such as Roche, Novartis, Bayer, Merck Serono, Alexion, Takeda, Nestlé and Medtronic.
Before joining Cambridge Enterprise, Dafne worked as a Market Intelligence Analyst at Debiopharm International and as a Project Manager at Alcimed.
Dafne obtained a PhD in Biology from the Institute Curie (Paris, France) and the University Paris XI (Paris, France).
Dafne joined Cambridge Enterprise in January 2017.
Katja assists academics at the University to turn ideas and inventions emerging from the life sciences into commercial opportunities. Together with her colleagues in the Life Sciences team, Katja provides support for the evaluation, protection and licensing of technologies to achieve global impact.
Since joining Cambridge Enterprise, Katja has worked closely with academics in order to support translational research funding applications, protect inventions via patenting and support the marketing and licensing of technologies arising from the University. Katja also helps academics to access Cambridge Enterprise’s network of expertise by connecting them with Entrepreneurs in Residence, consultants and mentors as well as University programmes such as iTeams Cambridge, Experts in Residence at the Cambridge Academy of Therapeutic Sciences, and EnterpriseTECH at Cambridge Judge Business School.
Prior to joining Cambridge Enterprise, Katja worked as a postdoctoral researcher at Queen Mary University of London in the field of microvascular research, investigating the role of endothelial junctional proteins in inflammatory diseases.
Katja studied Biology with a focus on Human and Molecular Biology at the Saarland University in Germany with research projects in the area of prostate cancer and obesity. She holds a PhD in Biochemistry from the Leipzig University in Germany having worked on novel peptide-drug conjugates and therapeutic peptides in the fields of breast cancer and obesity. During her PhD she has worked in collaboration with non-university research institutes such as the Helmholtz Centre for Environmental Research as well as small biotech and pharma companies. She is co-author on six academic publications.
Katja joined Cambridge Enterprise in March 2018.
Emma is a Commercialisation Associate in the Life Sciences team, providing support for the evaluation of new technologies, protection of intellectual property and developing commercial opportunities arising from University research.
Prior to joining Cambridge Enterprise, Emma spent more than two years as a trainee patent attorney at a top tier UK patent law firm. She previously completed a PhD and short post-doctoral research position in Plant Genetics at the University of Cambridge. She also has a BA in Biological Natural Sciences from the University of Cambridge.
She is an author on five academic publications and is a part-qualified UK and European patent attorney.
Emma joined Cambridge Enterprise in March 2022.
Laura is a Commercialisation Associate in the Life Sciences team, working in identifying, evaluating and protecting intellectual property with commercial potential arising from research at the University of Cambridge. This also involves the development and support of academic and commercial relationships and opportunities.
Prior to joining Cambridge Enterprise, Laura was a postdoctoral researcher in ovarian cancer at the Weatherall Institute of Molecular Medicine (WIMM), University of Oxford. She completed a Doctoral Training Programme (DTP) DPhil in Interdisciplinary Bioscience after being competitively awarded two doctoral scholarships by the BBSRC (Biotechnology and Biological Sciences Research Council) and the University of Oxford. Her DPhil work focused on the use of single-cell genomic tools to study the molecular biology and pathology of the female reproductive tract. Before doing her PhD, she was an Oxford Martin School Research Fellow and did her undergraduate degree in Biotechnology at the University Pablo de Olavide in Seville, Spain.
Laura joined Cambridge Enterprise in January 2022.
Aditi is a Commercialisation Associate working with Cambridge Enterprise and Cancer research UK, providing support for the evaluation of new technologies, protection of intellectual property and developing commercial opportunities arising from University research.
Prior to joining Cambridge Enterprise Aditi worked for a consulting start up assisting SMEs receive European Innovation Council funding. Aditi has also worked as a Technology specialist for a leading patent law firm in Japan.
Aditi received here PhD in Chemical Biology from the University of Illinois Urbana-Champaign. Her PhD work focused on studying RNA protein interaction. During her PhD, she also interned as a Commercialisation Analyst for the Office of Technology Management at the University of Illinois Urbana-Champaign.
Aditi joined Cambridge Enterprise in September 2022.
Nicola is responsible for the coordination of our Life Sciences intellectual property portfolio held by Cambridge Enterprise on behalf of the University. She is a member of Business Support, the team responsible for business intelligence as well as the administration and management of our portfolio of inventions, patents and agreements.
Nicola coordinates the execution of commercial and internal agreements put in place in relation to our Life Sciences portfolio, as well as ensuring the relevant data is captured and maintained, thereby contributing to the integrity of Cambridge Enterprise’s portfolio data.
Nicola joined Cambridge Enterprise in April 2019.
Marcio leads the Physical Sciences team at Cambridge Enterprise, working to help researchers commercialise technologies from across the whole range of the Schools of Physical Sciences and Technology.
Prior to joining Cambridge Enterprise, Marcio was with Imperial College London in a similar role for close to two years. Before that, Marcio enjoyed working in his own company in the field of scientific instrumentation for high pressure research, from where he exited in 2018, after 16 years. At the time of his exit the company had offices in the UK, US, Belgium and China. Previous to this, he worked for a medical devices company with full new product development and introduction responsibilities.
His scientific background is in physics, with a PhD from Royal Holloway, University of London. He also has an MBA from the University of Surrey and is a Certified Licensing Professional.
Marcio joined Cambridge Enterprise in March 2021.
Gillian is the Commercialisation Director of the Technology Transfer Team, working with researchers to help them commercialise their research.
She has worked with scientists in the Physical Sciences space to bring together teams that have turned research ideas into investible opportunities, such as aqdot, Silicon Microgravity and Fluidic Analytics.
Gillian has previously worked in technical and business development roles in both small and multinational companies in the UK, US and Japan.
She holds a BA in Natural Sciences from Oxford University, a doctorate in laser application and an MBA.
Gillian joined Cambridge Enterprise in 2009.
Maggie works with researchers across the range of physical sciences to help them achieve impact from their research by building relationships with commercial organisations.
During her time at Cambridge Enterprise, Maggie has led the licensing of university technologies to companies such as Lamina Dielectrics, Cambridge Graphene, Aurelius Environmental, and TE Wire & Cable (for a new design of thermocouple). Maggie has also supported the formation of spin-out companies such as Metalysis, Enval, and Porotech (who won the 2018 postdoc business plan competition).
Prior to joining Cambridge Enterprise, Maggie worked for 10 years at a multinational oil company in various roles, initially working to develop new automotive fuel and oil products, and later in the analysis of environmental and economic data to help formulate business strategy.
She has a scientific background in physics, holding two degrees from the University of Cambridge: an MA in Natural Sciences, and a PhD in solid state physics.
Maggie joined the Technology Transfer Office of the University, which later became Cambridge Enterprise, in March 2001.
Ed is a Business Development Manager and is responsible for increasing revenue generation from technology licenses.
Prior to joining Cambridge Enterprise, Ed worked for a multinational wood pulp company, specialising in biorefinery technology and leading R&D teams in the UK, the Netherlands and Austria, with scale up piloting in both North America and South Africa. The underpinning science for these projects was originally developed in a start-up company that Ed co-founded to commercialise some of his academic research from Imperial College London.
From 2005-2010 Ed was a lecturer in Green Chemistry at Imperial and he holds a PhD in Polymer Chemistry from Durham University. He has co-authored >60 academic papers and patents.
Ed joined Cambridge Enterprise in November 2022.
Nathalie is a Commercialisation and Outreach Manager, focusing on making Cambridge University’s researchers, academics and students aware of how Cambridge Enterprise can help them.
Before she joined Cambridge Enterprise Nathalie worked with a specialised engineering company in the secure printing industry, taking a technology to market that had received a substantial Horizon2020 grant. Prior to that she ran a start-up technology platform connecting print to digital, with applications in smart packaging. Before that she worked as a management consultant to the chemicals, healthcare and energy industries.
Nathalie has a PhD in theoretical physics from the University of Amsterdam.
She joined Cambridge Enterprise in November 2022.
Adam is a Commercialisation Manager in the Physical Sciences Team where he works to commercialise technologies from across the physical sciences.
Prior to joining Cambridge Enterprise, Adam spent approximately fifteen years working in industrial and academic research and innovation settings. He previously worked as Head of Research Programme and CIH Programme Lead for the Centre for Digital Built Britain, funding and managing innovative research as a partner organisation in the £72m Innovate UK-funded Construction Innovation Hub. His work contributed to UKRI’s Transforming Construction Challenge, ensuring industrial impact from academic research, aiming to transform the construction industry via innovative digital tools and ways of working.
Prior to this he was Senior Specialist at Beko, where he was involved in setting up and running parent company Arçelik’s first international R&D centre in Cambridge, developing technologies and new products in collaboration with academic partners and start-ups. He previously worked at Nokia, where he was responsible for developing inventions for Nokia’s next-generation devices. This followed a period of academic post-doctoral research at Cambridge University across a range of topics including novel nanostructures, solar cells, superconductivity, flexible electronic devices and bioimplants, and insect biomechanics.
Adam is trained as a physicist with an MPhys from Lancaster University, a PhD in experimental physics from the University of Bristol, and is a Chartered Physicist.
Adam joined the Cambridge Enterprise team in July 2020.
Jennie works closely with others in both the Physical and Life Sciences teams to support commercialisation of research outputs primarily from the School of Physical Sciences and the School of Technology in the University of Cambridge.
With a focus on creating positive societal impact, Jennie is proactive in assessing technology with the most potential to be disruptive, and then working closely with our academic and internal stakeholders to find the best routes to market.
Prior to joining Cambridge Enterprise, Jennie worked as a Product Specialist for a major biotechnology company, with an emphasis on global regulatory compliance.
Jennie has a Masters degree in Chemistry from the University of Sussex and a PhD in Chemistry from the University of Cambridge. Jennie’s Master’s research focused on quantum dot synthesis for single molecule fluorescence applications for her Masters. This led her to study the aggregation of amyloid beta 42 (a peptide implicated in Alzheimer’s Disease) using single molecule fluorescence techniques and microfluidics during her PhD.
Jennie joined Cambridge Enterprise in August 2016.
As a Commercialisation Associate Elena helps inventors and academics commercialise their exciting discoveries.
Elena spent some time trying to commercialise her own PhD work which first exposed her to the sensational enterprise ecosystem around Cambridge. During her PhD, Elena developed transparent and flexible sensors, largely for consumer electronics applications, in the Materials department at Imperial College London. Her master’s and bachelor’s degrees are in Chemistry with Nanotechnology from Heriot Watt University in Edinburgh.
Elena joined Cambridge Enterprise in January 2023.
Matt is a Commercialisation Associate, his role involves taking novel and exciting research from across the schools of physical sciences and looking at how it can be commercialised to have a positive real world impact.
Before joining Cambridge Enterprise Matt worked at a life science marketing company as an inbound marketing consultant. Here he learnt the basics of marketing and developed his ability to evaluate and identify markets, for the products and services of life sciences companies. Prior to this Matt was working on a research project looking to create a model that would help to identify the origin of life.
Matt has an MPhil from the University of Cambridge in Micro and Nanotechnology Enterprise and a BSc from the University of Strathclyde in Chemistry.
Matt joined Cambridge Enterprise in January 2022.
Oleksandra is a Commercialisation Associate in the Physical Sciences team.
Prior to joining Cambridge Enterprise Oleksandra worked as a scientist in Corporate Venturing team at Cambridge Display Technology (CDT) Ltd where she was looking for start-up companies to partner with for CDT’s parent company Sumitomo Chemical. She also worked as a chemist in Organic Photodiode team, designing and synthesising new photoactive materials.
Oleksandra holds a PhD in chemistry/photophysics from the University of Sheffield. She also has BSc in Chemistry from Taras Shevchenko National University of Kyiv (Ukraine) and MSc in Applied Chemistry from Kaunas University of Technology (Lithuania).
Oleksandra joined Cambridge Enterprise in August 2022.
Sarah is a Commercialisation Associate in the Physical Sciences team and is responsible for identifying and commercialising Intellectual Property of commercial value.
Prior to joining Cambridge Enterprise, Sarah worked as an Assay Scientist for the world’s top selling brand in home pregnancy and fertility tests. She has also worked for a healthcare company working on polymer formulations for medical adhesives.
Sarah has an MSc in Polymer Chemistry with a research paper on Covalent attachment to Porous Polymer Scaffolds for In-vitro Cell Culture. Sarah has also completed the Intellectual Property Law Post Graduate Certificate, which gives her full exemption from the foundation level examinations for the qualification as a patent or trademark attorney in the U.K (IPReg/CIPA/CITMA).
Sarah joined Cambridge Enterprise in July 2021.
Tim is a Senior Commercialisation Associate, working to help turn exciting discoveries in the Physical Sciences into real-world impact through commercialisation.
Prior to joining Cambridge Enterprise, Tim worked in research at the National Physical Laboratory, developing advanced spectroscopic techniques for measuring electrochemical devices such as hydrogen fuel cells and batteries during operation. He applied these techniques in collaboration with academic and industrial partners. This followed postdoctoral appointments at the University of Tokyo in Japan and CEA Grenoble in France, the former funded by a JSPS Fellowship.
Tim has a PhD in Chemistry from the University of Cambridge, working on solar fuels production, which followed a Masters degree in Chemistry from the University of Oxford.
Tim joined Cambridge Enterprise in March 2021.
Natalie is responsible for the coordination of our Physical Sciences intellectual property portfolio held by Cambridge Enterprise on behalf of the University. She is a member of Business Support, the team responsible for business intelligence as well as the administration and management of our portfolio of inventions, patents and agreements.
Natalie coordinates the execution of commercial and internal agreements put in place in relation to our Physical Sciences portfolio, as well as ensuring the relevant data is captured and maintained, thereby contributing to the integrity of Cambridge Enterprise’s portfolio data.
Prior to her current position, Natalie worked in several companies from heavy industry to medical materials in product development.
Natalie has a Master’s degree in Materials Science and Engineering from the University of Sheffield.
Natalie joined Cambridge Enterprise in September 2013.
Liz job shares the role of PA to the Technology Transfer team with Zoe Prior.
Liz has 15 years of executive assistant experience within investment banking in the City of London. Before starting work with Cambridge Enterprise, Liz worked at Cambridge & Peterborough NHS Foundation Trust in Mental Health for the Head of Professional Nursing and the Trust Lead for Allied Health Professions.
Liz joined Cambridge Enterprise in 2014.
Zoe shares the role of PA to the Technology Transfer team with Liz Barker.
Zoe has experience in supporting and leading teams and before joining Cambridge Enterprise was PA to the CEO and Office Manager at software company, IPV. Prior to this, her roles included Team Leader within the HR Department at Anglian Water and People Team Coordinator at Redgate Software.
Zoe holds an ISEB Programme and Project Management qualification.
Zoe joined Cambridge Enterprise in October 2019.
Currently on maternity leave.
PA (Job Share with Liz Barker and Zoe Prior) to Dr Iain Thomas, Head of Life Sciences, Dr Marcio Siqueira, Head of Physical Sciences and The Technology Transfer Team.
Prior to joining Cambridge Enterprise she spent 2 ½ years working for the Local Authority in Children’s Services, and has a range of administrative experience working in both healthcare and retail sectors.
Anna joined Cambridge Enterprise in July 2022.
Louise is Director of Ceres Agri-Tech, a knowledge-exchange partnership for the agri-tech sector that helps to connect industry to academia, and funds resulting collaborative projects in order to take technology to market.
Previously, Louise chaired the Red Tractor Fresh Produce Scheme and was a member of the Assured Food Standards Board. In addition Louise spent 10 years working at Marks and Spencer plc in a number of technical and commercial roles across their Food Business.
Louise has a PhD in Plant Pathology from the University of Reading and enjoyed post doc positions at the Forestry Commission working on novel biocontrol systems for tree diseases.
Outside of Cambridge Enterprise, Louise chairs the AHDB Soft Fruit Research Advisory Panel and is a member of the AHDB Hort Board. She also chairs the Raspberry Breeding Consortium at James Hutton Ltd, which is a joint research and industry consortium.
Louise joined Cambridge Enterprise in June 2019.
Marcio leads the Physical Sciences team at Cambridge Enterprise, working to help researchers commercialise technologies from across the whole range of the Schools of Physical Sciences and Technology.
Prior to joining Cambridge Enterprise, Marcio was with Imperial College London in a similar role for close to two years. Before that, Marcio enjoyed working in his own company in the field of scientific instrumentation for high pressure research, from where he exited in 2018, after 16 years. At the time of his exit the company had offices in the UK, US, Belgium and China. Previous to this, he worked for a medical devices company with full new product development and introduction responsibilities.
His scientific background is in physics, with a PhD from Royal Holloway, University of London. He also has an MBA from the University of Surrey and is a Certified Licensing Professional.
Marcio joined Cambridge Enterprise in March 2021.
Emma is Commercialisation Manager (AHSS).
Her role is to develop and enhance Cambridge Enterprise’s support for academics, researchers and students in the Arts, Humanities and Social Sciences, with the aim of enabling creative engagements between Cambridge researchers and beneficiaries in business, government and policy, the voluntary and community sector, and wider society.
Prior to joining Cambridge Enterprise, Emma was College Lecturer in Theology at Keble College, Oxford and Lecturer in English at Middlebury College’s Oxford Humanities Programme. She also worked in outreach, public engagement and student recruitment at Cambridge’s Faculty of Divinity.
Emma holds a PhD from the Faculty of English, University of Cambridge. Her monograph, a study of eighteenth-century religious and literary culture, appeared in 2017. She is Executive Secretary of the British Society of Eighteenth-Century Studies.
Emma joined Cambridge Enterprise in December 2018.
Dom is a Commercialisation Associate (Arts, Humanities and Social Sciences).
His role is to provide support in the identification and evaluation of new technologies, protection of intellectual property, and developing commercial opportunities arising from Arts, Humanities, and Social Science research.
Prior to joining Cambridge Enterprise, Dom spent two years as a Strategic Communications Associate at a leading global public relations and communications consultancy. He is currently undertaking an MPhil in Digital Humanities at the University of Cambridge. He completed his BA (Hons) in History at the University of Warwick.
Dom joined Cambridge Enterprise in March 2023.
Suzy is responsible for the archiving of technology transfer cases and the maintenance of systematic and orderly records of new and existing technology transfer related documents.
She also provides secretarial, data entry and administrative support to members of the Business Support team during absences and as and when needed.
Prior to her current position, she co-ordinated travel, meeting bookings and visitor arrangements.
Suzy joined Cambridge Enterprise in May 2011.